AAO Data: Experimental RNA Based Drug Addresses the Underlying Cause of Rare Eye Disease

At the virtual AAO 2020 meeting, ProQR Therapeutics will present two posters on its lead product candidate sepofarsen for the treatment of the root cause of Leber congenital amaurosis 10 (LCA10), a rare eye disease that damages the development of the retina and causes severe vision loss.

Presentation details:

Presentation Title: Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10)

• Session: The poster presentation will be available on the AAO meeting portal starting November 11, 2020

Presentation Title: Full-field stimulus testing (FST) to assess sepofarsen patient response in Leber congenital amaurosis type 10 (LCA10)

• Session: The poster presentation will be available on the AAO meeting portal starting November 11, 2020